PE20050231A1 - Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 - Google Patents
Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3Info
- Publication number
- PE20050231A1 PE20050231A1 PE2004000611A PE2004000611A PE20050231A1 PE 20050231 A1 PE20050231 A1 PE 20050231A1 PE 2004000611 A PE2004000611 A PE 2004000611A PE 2004000611 A PE2004000611 A PE 2004000611A PE 20050231 A1 PE20050231 A1 PE 20050231A1
- Authority
- PE
- Peru
- Prior art keywords
- hydroxy
- alkyl
- piperidinium
- diphenyl
- methyl
- Prior art date
Links
- 102000007202 Muscarinic M3 Receptor Human genes 0.000 title 1
- 108010008405 Muscarinic M3 Receptor Proteins 0.000 title 1
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical class C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 title 1
- RWRDLPDLKQPQOW-UHFFFAOYSA-O Pyrrolidinium ion Chemical compound C1CC[NH2+]C1 RWRDLPDLKQPQOW-UHFFFAOYSA-O 0.000 title 1
- 239000005557 antagonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 abstract 2
- 239000004480 active ingredient Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical class [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000003551 muscarinic effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
- C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
- C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/40—Oxygen atoms
- C07D211/44—Oxygen atoms attached in position 4
- C07D211/46—Oxygen atoms attached in position 4 having a hydrogen atom as the second substituent in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Otolaryngology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
REFERIDA A COMPUESTOS DE FORMULA I EN FORMA DE SAL O ZWITERIONICA DONDE R1 Y R3 SON CADA UNO UN GRUPO CARBOCICLICO C3-C15, GRUPO HETEROCICLICO C5-C12; R2 ES H, HIDROXI, ALQUILO C1-C4; L Y M SON CADA UNO (UN ENLACE Y -CH2-CH2-), (-CH2- Y -CH2-CH2-) O (-CH2-CH2- Y -CH2-) RESPECTIVAMENTE; J ES ALQUILENO C1-C2, O UN ENLACE; R4 ES ALQUILO C1-C4; R5 ES ALQUILO C1-C10, HETEROCICLICO DE 5 A 12 MIEMBROS, ALQUENILO C2-C10 ENTRE OTROS. TAMBIEN REFERIDA A UNA COMPOSICION FARMACEUTICA CON COMPUESTOS ANTERIORES COMO INGREDIENTES ACTIVOS DONDE LOS PREFERIDOS SON: BROMURO(1a,1b) DE CIS Y TRANS-4-(2-HIDROXI-2,2-DIFENIL-ACETOXI)-1-METIL-1-(2-FENOXI-ETIL)-PIPERIDINIO; TRIFLUOROACETATO DE (S)-2-(2-HIDROXI-2,2-DIFENIL-ACETOXIMETIL)-1-METIL-1-OCT-2-INIL-PIRROLIDINIO Y BROMURO DE (1S/R,3R)-3-(2-HIDROXI-2,2-DIFENIL-ACETOXI)-1-METIL-1-(2-FENOXI-ETIL)-PIPERIDINIO; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO DE CONDICIONES MEDIADAS POR EL RECEPTOR M3 MUSCARINICO
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0314697A GB0314697D0 (en) | 2003-06-24 | 2003-06-24 | Organic compounds |
| GB0327526A GB0327526D0 (en) | 2003-11-26 | 2003-11-26 | Organic compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20050231A1 true PE20050231A1 (es) | 2005-05-20 |
Family
ID=33554160
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2004000611A PE20050231A1 (es) | 2003-06-24 | 2004-06-22 | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7947730B2 (es) |
| EP (1) | EP1638940B1 (es) |
| JP (1) | JP2008529965A (es) |
| AR (1) | AR044851A1 (es) |
| AT (1) | ATE478845T1 (es) |
| AU (1) | AU2004251867B2 (es) |
| BR (1) | BRPI0411738A (es) |
| CA (1) | CA2526991C (es) |
| DE (1) | DE602004028821D1 (es) |
| MX (1) | MXPA05013823A (es) |
| PE (1) | PE20050231A1 (es) |
| PL (1) | PL1638940T3 (es) |
| PT (1) | PT1638940E (es) |
| TW (1) | TW200526573A (es) |
| WO (1) | WO2005000815A2 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0410712D0 (en) | 2004-05-13 | 2004-06-16 | Novartis Ag | Organic compounds |
| GB0428418D0 (en) * | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| GB0428416D0 (en) * | 2004-12-24 | 2005-02-02 | Novartis Ag | Organic compounds |
| US7399861B2 (en) | 2005-11-10 | 2008-07-15 | Bodor Nicholas S | Soft anticholinergic esters |
| CA2627982C (en) | 2005-11-10 | 2013-09-10 | Nicholas S. Bodor | Soft anticholinergic esters |
| US20090182033A1 (en) * | 2005-12-16 | 2009-07-16 | Argenta Discovery Ltd. | Cyclic Amine Derivatives and Their Uses |
| EP2013172A4 (en) * | 2006-04-24 | 2010-08-04 | Astrazeneca Ab | NEW ALKYLESTERS FROM CYCLIC AMINO ALCOHOLS WITH MUSCARIN M3 RECEPTORANTAGONOSTIC ACTIVITY FOR THE TREATMENT OF CHRONIC BRONCHIA SUPPRESSION, ASTHMA OR OVERACTIVE HARNBASE |
| TW200825084A (en) | 2006-11-14 | 2008-06-16 | Astrazeneca Ab | New compounds 521 |
| US20100112061A1 (en) * | 2006-12-13 | 2010-05-06 | William Baker | Monophosphates as Mutual Prodrugs of Muscarinic Receptor Antagonists and Beta-Agonists for the Treatment of COPD And Chronic Bronchitis |
| KR101495708B1 (ko) * | 2007-02-23 | 2015-02-25 | 세라밴스 바이오파마 알앤디 아이피, 엘엘씨 | 무스카린 수용체 안타고니스트로 유용한 4차 암모늄 디페닐메틸 화합물 |
| PT2197841E (pt) * | 2007-09-07 | 2012-01-02 | Theravance Inc | Compostos contendo guanidina úteis como antagonistas do receptor muscarínico |
| JP2011506477A (ja) | 2007-12-14 | 2011-03-03 | セラヴァンス， インコーポレーテッド | ムスカリン受容体拮抗薬として有用なアミジン含有化合物 |
| JP4837800B2 (ja) | 2008-05-13 | 2011-12-14 | アストラゼネカ・アクチエボラーグ | ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体 |
| WO2010126025A1 (ja) * | 2009-04-30 | 2010-11-04 | 帝人ファーマ株式会社 | 四級アンモニウム塩化合物 |
| US9156833B2 (en) | 2012-07-16 | 2015-10-13 | Barry University, Inc. | Bitopic muscarinic agonists and antagonists and methods of synthesis and use thereof |
| ES2897697T3 (es) | 2015-07-03 | 2022-03-02 | Novartis Ag | Inhalador adaptado para leer información almacenada en un medio de almacenamiento de datos de un recipiente |
| BR112021017772A2 (pt) | 2019-03-11 | 2021-11-16 | Nocion Therapeutics Inc | Bloqueadores de canais de íons carregados e métodos para uso |
| JP7513713B2 (ja) | 2019-11-06 | 2024-07-09 | ノシオン セラピューティクス，インコーポレイテッド | 荷電したイオンチャンネル遮断薬および使用方法 |
| BR112022017801A2 (pt) * | 2020-03-11 | 2022-10-25 | Nocion Therapeutics Inc | Bloqueadores de canais de íons carregados e métodos para uso |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3240784A (en) * | 1966-03-15 | Esters of quaternary z-hydroxy methyl piperidinium compounds | ||
| US2746966A (en) * | 1953-11-02 | 1956-05-22 | Lakeside Lab Inc | Esters of bis-(nu-substituted-3-hydroxypiperidinium) alkanes |
| GB833820A (en) * | 1957-10-17 | 1960-04-27 | Beecham Res Lab | Improvements in or relating to the preparation of pyrrolidyl esters and quaternary compounds thereof |
| JPS6018661B2 (ja) * | 1976-01-01 | 1985-05-11 | 太田製薬株式会社 | １−（１，３−ジオキソラン−４−イルメチル）ピペリジノ−ル誘導体 |
| JPS5427570A (en) * | 1977-07-30 | 1979-03-01 | Ota Pharma | Stereoisomer of 44acyloxyy11 alkyll11*1*33dioxolanee44 ylmethyl* pideridinium salt derivative |
| JPS5679688A (en) * | 1979-12-04 | 1981-06-30 | Ota Seiyaku Kk | 4-acyloxy-1- 1,3-dioxoran-2-ylmethyl piperidine derivative and its production |
| JPS5835177A (ja) * | 1981-08-26 | 1983-03-01 | Dainippon Pharmaceut Co Ltd | ２−環状アミノ−２−（１，２−ベンズイソキサゾ−ル−３−イル）酢酸エステル類並びにその酸付加塩類および第４級アンモニウム塩類 |
| JPS58208270A (ja) * | 1982-05-28 | 1983-12-03 | Dainippon Pharmaceut Co Ltd | α−環状アミノフエニル酢酸エステル類並びにその酸付加塩類及び第４級アンモニウム塩類 |
| GB9023023D0 (en) | 1990-10-23 | 1990-12-05 | Barlow Richard B | Pharmaceutical compositions |
| EP0823423B1 (en) | 1995-04-28 | 2004-06-16 | Banyu Pharmaceutical Co., Ltd. | 1,4-disubstituted piperidine derivatives |
| DE59709927D1 (de) * | 1996-11-11 | 2003-05-28 | Noe Christian | Verwendung eines pharmazeutisch geeigneten Salzes von (3R,2'R)-3-[(Cyclopentyl-hydroxyphenylacetyl)oxy]-1,1-dimethyl-pyrrolidinium zur Herstellung eines Arzneimittels |
| CA2415468A1 (en) * | 2000-07-11 | 2003-01-10 | Yoshio Ogino | Ester derivatives |
| ES2206021B1 (es) * | 2002-04-16 | 2005-08-01 | Almirall Prodesfarma, S.A. | Nuevos derivados de pirrolidinio. |
| US7399861B2 (en) * | 2005-11-10 | 2008-07-15 | Bodor Nicholas S | Soft anticholinergic esters |
-
2004
- 2004-06-22 AR ARP040102162A patent/AR044851A1/es not_active Application Discontinuation
- 2004-06-22 PE PE2004000611A patent/PE20050231A1/es not_active Application Discontinuation
- 2004-06-23 AU AU2004251867A patent/AU2004251867B2/en not_active Ceased
- 2004-06-23 EP EP04740214A patent/EP1638940B1/en not_active Expired - Lifetime
- 2004-06-23 US US10/561,366 patent/US7947730B2/en not_active Expired - Fee Related
- 2004-06-23 PL PL04740214T patent/PL1638940T3/pl unknown
- 2004-06-23 PT PT04740214T patent/PT1638940E/pt unknown
- 2004-06-23 CA CA2526991A patent/CA2526991C/en not_active Expired - Fee Related
- 2004-06-23 JP JP2006516038A patent/JP2008529965A/ja active Pending
- 2004-06-23 BR BRPI0411738-7A patent/BRPI0411738A/pt not_active Application Discontinuation
- 2004-06-23 AT AT04740214T patent/ATE478845T1/de active
- 2004-06-23 WO PCT/EP2004/006795 patent/WO2005000815A2/en not_active Ceased
- 2004-06-23 DE DE602004028821T patent/DE602004028821D1/de not_active Expired - Lifetime
- 2004-06-23 MX MXPA05013823A patent/MXPA05013823A/es active IP Right Grant
- 2004-06-23 TW TW093118142A patent/TW200526573A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2526991A1 (en) | 2005-01-06 |
| US20060287362A1 (en) | 2006-12-21 |
| EP1638940A2 (en) | 2006-03-29 |
| JP2008529965A (ja) | 2008-08-07 |
| WO2005000815A3 (en) | 2005-04-14 |
| ATE478845T1 (de) | 2010-09-15 |
| DE602004028821D1 (de) | 2010-10-07 |
| BRPI0411738A (pt) | 2006-08-08 |
| MXPA05013823A (es) | 2006-02-28 |
| AR044851A1 (es) | 2005-10-05 |
| WO2005000815A2 (en) | 2005-01-06 |
| AU2004251867A1 (en) | 2005-01-06 |
| PL1638940T3 (pl) | 2011-02-28 |
| AU2004251867B2 (en) | 2008-08-07 |
| EP1638940B1 (en) | 2010-08-25 |
| US7947730B2 (en) | 2011-05-24 |
| PT1638940E (pt) | 2010-11-08 |
| TW200526573A (en) | 2005-08-16 |
| CA2526991C (en) | 2012-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20050231A1 (es) | Derivados de piperidinium y pirrolidinium como antagonistas del receptor muscarinico m3 | |
| PE20070218A1 (es) | COMPUESTOS DE CICLOALQUILO AMINO-HIDANTOINA Y USO DE ESTOS PARA LA MODULACION DE ß-SECRETASA | |
| PE20050874A1 (es) | Compuestos de bencimidazolona que tienen actividad agonista del receptor 5-ht4 | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR046711A1 (es) | 5-7-diaminopirazolo[4,3d]pirimidinas como inhibidores de la pde-5,composiciones farmaceuticas que las contienen y usos en el tratamiento de hipertensiones | |
| PE20091884A1 (es) | Antagonistas de cgrp seleccionados, procedimiento para su preparacion, asi como su uso como medicamento | |
| CR9459A (es) | Derivados benzodioxano y benzodioxolano y usos de los mismos | |
| PE20070217A1 (es) | Derivados de isoquinolona sustituidos con piperidinilo | |
| PE20090620A1 (es) | Derivados de 1,2,4,5-tetrahidro-3h-benzazepinas, su procedimiento de preparacion y las composiciones farmaceuticas que las contienen | |
| PE20071245A1 (es) | COMPUESTOS INDOL SULFONAMIDA COMO MODULADORES DEL RECEPTOR DE PROGESTERONA SELECTIVOS (SPRMs) | |
| PE20060691A1 (es) | Serinamidas sustituidas por benzoilo | |
| PE20070115A1 (es) | Derivados de [1,3,5]-triazina como inhibidores de aspartil proteasas | |
| PE20060383A1 (es) | Nuevos derivados amino de urea ciclicos como inhibidores de quinasa | |
| PE20071023A1 (es) | Azaciclilaminas-n-sustituidas como antagonistas de histamina-3 | |
| PE20071100A1 (es) | Derivados de azepinoindol como agentes farmaceuticos | |
| PE20080839A1 (es) | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas | |
| ECSP003828A (es) | Antagonistas de neurokinina selectivos | |
| PE20050999A1 (es) | Cetoamidas novedosas con p4 ciclicos como inhibidores de ns3 serina proteasa del virus de hepatitis c | |
| PE20080275A1 (es) | Derivados de 5h-benzo[4,5]ciclohepta[1,2]piridina como inhibidores de tirosina quinasa | |
| CO5680412A2 (es) | Agonistas del receptor adrenergico etilamino beta 2 sustituido con amino | |
| PE20060609A1 (es) | Derivados de quinuclidinas como antagonistas del receptor muscarinico (m3) | |
| PE20090482A1 (es) | Derivados heterociclicos como antagonistas del receptor ccr2 | |
| PE20070491A1 (es) | Compuestos derivados de 9-azabiciclo[3.3.1]nonano como inhibidores de la recaptacion de neurotransmisores de monoamina | |
| PE20060977A1 (es) | Derivados de piperidinilo como bloqueantes de canales de calcio | |
| PE20061316A1 (es) | Derivados de pirazol como antagonistas del receptor de progesterona |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration | ||
| FD | Application declared void or lapsed |